ArticleNeuropsychiatric disease and treatment2025
Evaluating the Therapeutic Efficacy of rTMS Combined with Low-Dose Antipsychotic Medication in Somatic Symptom Disorder.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Efficacy Study of Escitalopram Combined With Low-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Post-Ischemic Stroke Depression and Anxiety.Actas espanolas de psiquiatria · 2026Article
- Clinical Study on the Treatment of Somatisation Disorder With Repetitive Transcranial Magnetic Stimulation Combined With Venlafaxine.Actas espanolas de psiquiatria · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aim to evaluate the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) combined with low-dose antipsychotic medication in somatic symptom disorder (SSD) and its effects on neurotransmitters and inflammatory factors. Methods: This was a retrospective study. According to different treatment regimens, 90 patients with SSD were divided into a medication group (n = 45) and a combination group (n = 45). The medication group received low-dose antipsychotic medication, while the combination group received low-dose antipsychotic medication combined with rTMS. The primary outcomes were to compare the scores of the Hamilton Anxiety Rating Scale (HAMA) and the Hamilton Rating Scale for Depression (HAMD) between the two groups before and after intervention. The secondary outcomes involved assessing the quality of life of the two groups using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Neurotransmitters and inflammatory factors were measured using enzyme-linked immunosorbent assay. Clinical efficacy and adverse reaction rates were also compared. Results: After treatment, the combination group showed greater improvements in HAMA and HAMD scores, higher SF-36 scores across physical, social, psychological, and daily living dimensions, with increased levels of γ-aminobutyric acid and 5-hydroxytryptamine, decreased dopamine, lower levels of C-reactive protein and interleukin-1β, higher interleukin-10 levels (all Conclusion: rTMS combined with low-dose antipsychotic medication for SSD shows superiority over medication alone in improving anxiety and depression, enhancing quality of life, regulating neurotransmitter levels, and reducing inflammatory factors, with fewer side effects and significant clinical efficacy. However, due to the small sample size of this study, further prospective, randomized controlled studies with larger samples are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.